Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1β-blocking antibody canakinumab: Results of an open-label, parallel group, randomized, single-center study

Clinical and Vaccine Immunology

Volumn 17, Issue 12, 2010, Pages 1952-1957

  Chioato, A ^a   Noseda, E ^a   Felix, S D ^a   Stevens, M ^b   Del Giudice, G ^c   Fitoussi, S ^d   Kleinschmidt, A ^e  

^a NOVARTIS PHARMA AG   (Switzerland)

^b EMStat Ltd   (United Kingdom)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d MEDISCIS   (France)

^e GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC MENINGITIS; FLU LIKE SYNDROME; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DRUG INTERACTIONS; FEMALE; HEADACHE; HUMAN EXPERIMENTATION; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-1BETA; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 78649877154     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00175-10     Document Type: Article

References (26)

1. Abu-Shakra, M., J. Press, D. Buskila, and S. Sukenik. 2007. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun. Rev. 6:543-546.
2. Bongartz, T., A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285. (Pubitemid 43736578)
3. Centers for Disease Control and Prevention. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 49(RR06):1-54.
4. Chalmers, A., D. Scheifele, C. Patterson, D. Williams, J. Weber, R. Shuckett, and A. Teufel. 1994. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J. Rheumatol. 21:1203-1206. (Pubitemid 24234652)
5. De Gregorio, E., E. Tritto, and R. Rappuoli. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38:2068-2071.
6. Doran, M. F., C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel. 2002. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46:2287-2293.
7. Doran, M. F., C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel. 2002. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 46:2294-2300.
8. Efthimiou, R. A., A. Furlan, G. Gasbarrini, A. Gava, I. Koné-Paut, R. Manna, L. Punzi, F. S. Sutterwala, I. Touitou, and A. Doria. 2006. Autoinflammatory syndromes and infections: pathogenetic and clinical implications. Clin. Exp. Rheumatol. 26(Suppl. 48):S53-S61.
9. Eisenbarth, S. C., O. R. Colegio, W. O'Connor, F. S. Sutterwala, and R. A. Flavell. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122-1126.
10. Fomin, I., D. Caspi, V. Levy, N. Varsano, Y. Shalev, D. Paran, D. Levartovsky, I. Litinsky, I. Kaufman, I. Wigler, E. Mendelson, and O. Elkayam. 2006. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann. Rheum. Dis. 65:191-194.
11. Gluck, T., and U. Muller-Ladner. 2008. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin. Infect. Dis. 46:1459-1465.
12. Go, E. S., and Z. K. Ballas. 1996. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J. Allergy Clin. Immunol. 98:205-215.
13. Hernandez, C., A. S. Cetner, J. E. Jordan, S. N. Puangsuvan, and J. K. Robinson. 2008. Tuberculosis in the age of biologic therapy. J. Am. Acad. Dermatol. 59:363-380.
14. Kaine, J. L., A. J. Kivitz, C. Birbara, and A. Y. Luo. 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34:272-279.
15. Lachmann, H. J., I. Kone-Paut, J. B. Kuemmerle-Deschner, K. S. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, and P. N. Hawkins. 2009. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360:2416-2425.
16. Lachmann, H. J., P. Lowe, S. D. Felix, C. Rordorf, K. Leslie, S. Madhoo, H. Wittkowski, S. Bek, N. Hartmann, S. Bosset, P. N. Hawkins, and T. Jung. 2009. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206:1029-1036.
17. Li, H., S. B. Willingham, J. P. Ting, and F. Re. 2008. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181:17-21.
18. Makwana, N., and F. A. Riordan. 2007. Bacterial meningitis: the impact of vaccination. CNS Drugs 21:355-366.
19. Mease, P. J., C. T. Ritchlin, R. W. Martin, A. B. Gottlieb, S. W. Baumgartner, D. J. Burge, and J. B. Whitmore. 2004. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J. Rheumatol. 31:1356-1361.
20. Oren, S., M. Mandelboim, Y. Braun-Moscovici, D. Paran, J. Ablin, I. Litinsky, D. Comaneshter, D. Levartovsky, E. Mendelson, R. Azar, I. Wigler, A. Balbir-Gurman, D. Caspi, and O. Elkayam. 2008. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67:937-941.
21. Palmer, D. F., W. R. Dowle, M. T. Coleman, and G. C. Schild. 1975. Haemagglutination inhibition test, p. 25-62. Advanced laboratory techniques for influenza diagnosis. Procedural guide, pt. 2. U.S. Department of Health, Education and Welfare, Public Health Service, Atlanta, GA.
22. Salemi, S., A. Picchianti-Diamanti, V. Germano, I. Donatelli, A. Di Martino, M. Facchini, R. Nisini, R. Biselli, C. Ferlito, E. Podesta, A. Cappella, F. Milanetti, F. Rossi, R. Amodeo, F. Tabacco, R. Di Rosa, B. Lagana, and R. D'Amelio. 2010. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: safety and immunogenicity. Clin. Immunol. 134:113-120.
23. Salliot, C., M. Dougados, and L. Gossec. 2009. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 68:25-32.
24. Snape, M. D., K. P. Perrett, K. J. Ford, T. M. John, D. Pace, L. M. Yu, J. M. Langley, S. McNeil, P. M. Dull, F. Ceddia, A. Anemona, S. A. Halperin, S. Dobson, and A. J. Pollard. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173-184.
25. Tay, L., F. Leon, G. Vratsanos, R. Raymond, and M. Corbo. 2007. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res. Ther. 9:R38.
26. Woodard, J. L., and D. M. Berman. 2006. Prevention of meningococcal disease. Fetal Pediatr. Pathol. 25:311-319.